Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $25 price target on Spring Bank Pharmaceuticals after its R&D presentation yesterday. The analyst says the event highlighted the potency of inarigivir in Hepatitis B virus in patients as early as 12 weeks. Tenthoff further cites the final ACHIEVE data on the treatment likely coming at the EASL event in April of 2019, with additional studies taking place later next year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.